| 21.99 0.55 (2.57%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.95  |
1-year : | 33.81 |
| Resists | First : | 24.79 |
Second : | 28.95 |
| Pivot price | 20.19 |
|||
| Supports | First : | 20.72 |
Second : | 18.21 |
| MAs | MA(5) : | 21.38 |
MA(20) : | 20.49  |
| MA(100) : | 18.45 |
MA(250) : | 13.83 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 86.5 |
D(3) : | 75.3 |
| RSI | RSI(14): 57.6 |
|||
| 52-week | High : | 26.35 | Low : | 5.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NAMS ] has closed below upper band by 2.9%. Bollinger Bands are 20.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.11 - 22.2 | 22.2 - 22.28 |
| Low: | 20.89 - 21 | 21 - 21.09 |
| Close: | 21.8 - 21.98 | 21.98 - 22.13 |
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Tue, 09 Apr 2024
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal - GlobeNewswire
Mon, 01 Apr 2024
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer - GlobeNewswire
Mon, 01 Apr 2024
NewAmsterdam Pharma Announces Executive Leadership Changes - TipRanks.com - TipRanks
Tue, 05 Mar 2024
NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations - Simply Wall St
Mon, 04 Mar 2024
NewAmsterdam Pharma Updates Investor Presentation Online - TipRanks.com - TipRanks
Sun, 03 Mar 2024
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 2.958e+007 (%) |
| Held by Institutions | 5.7 (%) |
| Shares Short | 367 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.8292e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 777.9 % |
| Return on Equity (ttm) | -27.8 % |
| Qtrly Rev. Growth | 1.409e+007 % |
| Gross Profit (p.s.) | 1360 |
| Sales Per Share | -2463 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -141 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.12 |
| Dividend | 0 |
| Forward Dividend | 337880 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|